Liposomal lupeol acetate and the use thereof in preparing drugs for rheumatoid arthritis
US10441540B2 · kind B2 · utility
0Cited by
1References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 7, 2014 |
| Grant date | Oct 15, 2019 |
| Priority date | — |
| Expiry date | Mar 26, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a liposomal lupeol acetate (Lipo-LA) and its use in the treatment or prevention of rheumatoid arthritis (RA). The liposomal lupeol acetate of the present invention especially inhibits inflammatory responses and osteoclast generation (osteoclastogenesis) in the progression of rheumatoid arthritis (RA) at a half dose of the un-capsulated lupeol acetate, which may significantly reduce the incidence of RA and improve the therapeutic efficacy of lupeol acetate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.